



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

March 1, 2021

Via E-mail

Mr. Pat Cotroneo  
Chief Financial Officer  
FibroGen, Inc.  
409 Illinois Street  
San Francisco, CA 94158

**Re:   FibroGen, Inc.**  
**Form 10-Q for the quarterly period ended September 30, 2020**  
**Exhibit No. 10.1 Collaboration Agreement**  
**Exhibit No. 10.2 License, Development and Commercialization Agreement**  
**Exhibit No. 10.3 License, Development and Commercialization Agreement**  
**Exhibit No. 10.4 License Agreement**  
**Exhibit No. 10.5 First Amendment to the May 23, 1997 License Agreement**  
**Exhibit No. 10.6 Amendment to Research and Commercialization Agreement**  
**Exhibit No. 10.7 License Agreement**  
**Exhibit No. 10.8 Amendment No. 2 to Master Supply Agreement**  
**Exhibit No. 10.9 Master Supply Agreement**  
**Filed November 5, 2020**  
**File No. 001-36740**

Dear Mr. Cotroneo:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance